Antioxidants in cervical cancer: Chemopreventive and chemotherapeutic effects of polyphenols

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 5, 2012, Pages 737-747

  Di Domenico, F ^a   Foppoli, C ^a   Coccia, R ^a   Perluigi, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; Cervical cancer; HPV; Oxidative stress; Polyphenol

Indexed keywords

CURCUMIN; CYCLOOXYGENASE 1; EPIGALLOCATECHIN GALLATE; FERULIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RESVERATROL; TRANSCRIPTION FACTOR NRF2;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLON CANCER; DNA BINDING; DRUG BIOAVAILABILITY; DRUG SAFETY; DRUG STRUCTURE; DUODENUM CANCER; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUTH CANCER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SOFT PALATE CANCER; TEA; THERAPY EFFECT; UTERINE CERVIX CANCER;

ALPHAPAPILLOMAVIRUS; ANTIOXIDANTS; FEMALE; HUMANS; POLYPHENOLS; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 84858149475     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.10.005     Document Type: Review

References (163)

1. zur Hausen H., Meinhof W., Scheiber W., Bornkamm G.W. Attempts to detect virus-specific DNA in human tumors. I. Nucleic acid hybridizations with complementary RNA of human wart virus. Int. J. Cancer 1974, 13:650-656.
2. Narisawa-Saito M., Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 2007, 98:1505-1511.
3. Bharti A.C., Shukla S., Mahata S., Hedau S., Das B.C. Anti-human papillomavirus therapeutics: facts & future. Indian J. Med. Res. 2009, 130:296-310.
4. Baak J.P., Kruse A.J., Robboy S.J., Janssen E.A., van Diermen B., Skaland I. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J. Clin. Pathol. 2006, 59:1017-1028.
5. Hamid N.A., Brown C., Gaston K. The regulation of cell proliferation by the papillomavirus early proteins. Cell Mol. Life Sci. 2009, 66:1700-1717.
6. Moody C.A., Laimins L.A. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 2010, 10:550-560.
7. Jayshree R.S., Sreenivas A., Tessy M., Krishna S. Cell intrinsic & extrinsic factors in cervical carcinogenesis. Indian J. Med. Res. 2009, 130:286-295.
8. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75:495-505.
9. Massimi P., Shai A., Lambert P., Banks L. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background. Oncogene 2008, 27:1800-1804.
10. Vogt M., Butz K., Dymalla S., Semzow J., Hoppe-Seyler F. Inhibition of Bax activity is crucial for the antiapoptotic function of the human papillomavirus E6 oncoprotein. Oncogene 2006, 25:4009-4015.
11. Thomas M., Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998, 17:2943-2954.
12. James M.A., Lee J.H., Klingelhutz A.J. Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J. Virol. 2006, 80:5301-5307.
13. Yuan H., Fu F., Zhuo J., Wang W., Nishitani J., An D.S., Chen I.S., Liu X. Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis. Oncogene 2005, 24:5069-5078.
14. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998, 12:2245-2262.
15. Giarre M., Caldeira S., Malanchi I., Ciccolini F., Leao M.J., Tommasino M. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle arrest. J. Virol. 2001, 75:4705-4712.
16. Balan R., Amalinei C., Giusca S.E., Ditescu D., Gheorghita V., Crauciuc E., Caruntu I.D. Immunohistochemical evaluation of COX-2 expression in HPV-positive cervical squamous intraepithelial lesions. Rom. J. Morphol. Embryol. 2011, 52:39-43.
17. Subbaramaiah K., Dannenberg A.J. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange. Cancer Res. 2007, 67:3976-3985.
18. Kim S.H., Oh J.M., No J.H., Bang Y.J., Juhnn Y.S., Song Y.S. Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 2009, 30:753-757.
19. Sudarshan S.R., Schlegel R., Liu X. The HPV-16 E5 protein represses expression of stress pathway genes XBP-1 and COX-2 in genital keratinocytes. Biochem. Biophys. Res. Commun. 2010, 399:617-622.
20. Moktar A., Singh R., Vadhanam M.V., Ravoori S., Lillard J.W., Gairola C.G., Gupta R.C. Cigarette smoke condensate-induced oxidative DNA damage and its removal in human cervical cancer cells. Int. J. Oncol. 2011, 39:941-947.
21. Beevi S.S., Rasheed M.H., Geetha A. Evidence of oxidative and nitrosative stress in patients with cervical squamous cell carcinoma. Clin. Chim. Acta 2007, 375:119-123.
22. Finkel T. Oxidant signals and oxidative stress. Curr. Opin. Cell Biol. 2003, 15:247-254.
23. Darr D., Fridovich I. Free radicals in cutaneous biology. J. Invest. Dermatol. 1994, 102:671-675.
24. Jurkiewicz B.A., Buettner G.R. Ultraviolet light-induced free radical formation in skin: an electron paramagnetic resonance study. Photochem. Photobiol. 1994, 59:1-4.
25. Beckman K.B., Ames B.N. Oxidative decay of DNA. J. Biol. Chem. 1997, 272:19633-19636.
26. Cadet J., Delatour T., Douki T., Gasparutto D., Pouget J.P., Ravanat J.L., Sauvaigo S. Hydroxyl radicals and DNA base damage. Mutat. Res. 1999, 424:9-21.
27. Vilenchik M.M., Knudson A.G. Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12871-12876.
28. Mates J.M., Perez-Gomez C., Nunez de Castro I. Antioxidant enzymes and human diseases. Clin. Biochem. 1999, 32:595-603.
29. Maynard S., Schurman S.H., Harboe C., de Souza-Pinto N.C., Bohr V.A. Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 2009, 30:2-10.
30. Storz P. Reactive oxygen species in tumor progression. Front. Biosci. 2005, 10:1881-1896.
31. Burdon R.H. Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic. Biol. Med. 1995, 18:775-794.
32. Toyokuni S., Okamoto K., Yodoi J., Hiai H. Persistent oxidative stress in cancer. FEBS Lett. 1995, 358:1-3.
33. Kryston T.B., Georgiev A.B., Pissis P., Georgakilas A.G. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat. Res. 2011, 711:193-201.
34. Liou G.Y., Storz P. Reactive oxygen species in cancer. Free. Radic. Res. 2010, 44:479-496.
35. Sgambato A., Zannoni G.F., Faraglia B., Camerini A., Tarquini E., Spada D., Cittadini A. Decreased expression of the CDK inhibitor p27Kip1 and increased oxidative DNA damage in the multistep process of cervical carcinogenesis. Gynecol. Oncol. 2004, 92:776-783.
36. Perluigi M., Giorgi A., Blarzino C., De Marco F., Foppoli C., Di Domenico F., Butterfield D.A., Schinina M.E., Cini C., Coccia R. Proteomics analysis of protein expression and specific protein oxidation in human papillomavirus transformed keratinocytes upon UVB irradiation. J. Cell. Mol. Med. 2009, 13:1809-1822.
37. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011, 11:85-95.
38. De Marco F., Perluigi M., Foppoli C., Blarzino C., Cini C., Coccia R., Venuti A. UVB irradiation down-regulates HPV-16 RNA expression: implications for malignant progression of transformed cells. Virus Res. 2007, 130:249-259.
39. Looi M.L., Mohd Dali A.Z., Md Ali S.A., Wan Ngah W.Z., Mohd Yusof Y.A. Oxidative damage and antioxidant status in patients with cervical intraepithelial neoplasia and carcinoma of the cervix. Eur. J. Cancer Prev. 2008, 17:555-560.
40. Kim S.Y., Kim J.W., Ko Y.S., Koo J.E., Chung H.Y., Lee-Kim Y.C. Changes in lipid peroxidation and antioxidant trace elements in serum of women with cervical intraepithelial neoplasia and invasive cancer. Nutr. Cancer 2003, 47:126-130.
41. Goncalves T.L., Erthal F., Corte C.L., Muller L.G., Piovezan C.M., Nogueira C.W., Rocha J.B. Involvement of oxidative stress in the pre-malignant and malignant states of cervical cancer in women. Clin. Biochem. 2005, 38:1071-1075.
42. Thomasset S.C., Berry D.P., Garcea G., Marczylo T., Steward W.P., Gescher A.J. Dietary polyphenolic phytochemicals-promising cancer chemopreventive agents in humans? A review of their clinical properties. Int. J. Cancer 2007, 120:451-458.
43. D'Archivio M., Santangelo C., Scazzocchio B., Vari R., Filesi C., Masella R., Giovannini C. Modulatory effects of polyphenols on apoptosis induction: relevance for cancer prevention. Int. J. Mol. Sci. 2008, 9:213-228.
44. Forman H.J., Torres M., Fukuto J. Redox signaling. Mol. Cell. Biochem. 2002, 234-235:49-62.
45. Nair S., Li W., Kong A.N. Natural dietary anti-cancer chemopreventive compounds: redox-mediated differential signaling mechanisms in cytoprotection of normal cells versus cytotoxicity in tumor cells. Acta Pharmacol. Sin. 2007, 28:459-472.
46. Gopalakrishnan A., Tony Kong A.N. Anticarcinogenesis by dietary phytochemicals: cytoprotection by Nrf2 in normal cells and cytotoxicity by modulation of transcription factors NF-kappa B and AP-1 in abnormal cancer cells. Food Chem. Toxicol. 2008, 46:1257-1270.
47. Hansen J.M., Watson W.H., Jones D.P. Compartmentation of Nrf-2 redox control: regulation of cytoplasmic activation by glutathione and DNA binding by thioredoxin-1. Toxicol. Sci. 2004, 82:308-317.
48. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 1995, 270:16483-16486.
49. Matthews J.R., Kaszubska W., Turcatti G., Wells T.N., Hay R.T. Role of cysteine62 in DNA recognition by the P50 subunit of NF-kappa B. Nucleic Acids Res. 1993, 21:1727-1734.
50. Hansen J.M., Go Y.M., Jones D.P. Nuclear and mitochondrial compartmentation of oxidative stress and redox signaling. Annu. Rev. Pharmacol. Toxicol. 2006, 46:215-234.
51. Sporn M.B. Carcinogenesis and cancer: different perspectives on the same disease. Cancer Res. 1991, 51:6215-6218.
52. Hu R., Zhou S., Li X. Altered Bcl-2 and Bax expression is associated with cultured first trimester human cytotrophoblasts apoptosis induced by hypoxia. Life Sci. 2006, 79:351-355.
53. Jeong W.S., Keum Y.S., Chen C., Jain M.R., Shen G., Kim J.H., Li W., Kong A.N. Differential expression and stability of endogenous nuclear factor E2-related factor 2 (Nrf2) by natural chemopreventive compounds in HepG2 human hepatoma cells. J. Biochem. Mol. Biol. 2005, 38:167-176.
54. Nair S., Xu C., Shen G., Hebbar V., Gopalakrishnan A., Hu R., Jain M.R., Lin W., Keum Y.S., Liew C., Chan J.Y., Kong A.N. Pharmacogenomics of phenolic antioxidant butylated hydroxyanisole (BHA) in the small intestine and liver of Nrf2 knockout and C57BL/6J mice. Pharm. Res. 2006, 23:2621-2637.
55. Shen G., Jeong W.S., Hu R., Kong A.N. Regulation of Nrf2, NF-kappaB, and AP-1 signaling pathways by chemopreventive agents. Antioxid. Redox Signal. 2005, 7:1648-1663.
56. Shen G., Xu C., Hu R., Jain M.R., Gopalkrishnan A., Nair S., Huang M.T., Chan J.Y., Kong A.N. Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. Mol. Cancer Ther. 2006, 5:39-51.
57. Siegel E.M., Salemi J.L., Villa L.L., Ferenczy A., Franco E.L., Giuliano A.R. Dietary consumption of antioxidant nutrients and risk of incident cervical intraepithelial neoplasia. Gynecol. Oncol. 2010, 118:289-294.
58. Tomita L.Y., Longatto Filho A., Costa M.C., Andreoli M.A., Villa L.L., Franco E.L., Cardoso M.A. Diet and serum micronutrients in relation to cervical neoplasia and cancer among low-income Brazilian women. Int. J. Cancer 2010, 126:703-714. Brazilian Investigation into Nutrition and Cervical Cancer Prevention (BRINCA) Study Team.
59. Goel A., Aggarwal B.B. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr. Cancer 2010, 62:919-930.
60. Zoberi I., Bradbury C.M., Curry H.A., Bisht K.S., Goswami P.C., Roti Roti J.L., Gius D. Radiosensitizing and anti-proliferative effects of resveratrol in two human cervical tumor cell lines. Cancer Lett. 2002, 175:165-173.
61. Brouet I., Ohshima H. Curcumin, an anti-tumour promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem. Biophys. Res. Commun. 1995, 206:533-540.
62. Sreejayan, Rao M.N. Nitric oxide scavenging bCBEy curcuminoids. J. Pharm. Pharmacol. 1997, 49:105-107.
63. Srivastava R., Dikshit M., Srimal R.C., Dhawan B.N. Anti-thrombotic effect of curcumin. Thromb. Res. 1985, 40:413-417.
64. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br. J. Pharmacol. 1998, 124:425-427.
65. Deodhar S.D., Sethi R., Srimal R.C. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J. Med. Res. 1980, 71:632-634.
66. Chan M.M., Adapala N.S., Fong D. Curcumin overcomes the inhibitory effect of nitric oxide on Leishmania. Parasitol. Res. 2005, 96:49-56.
67. Khafif A., Lev-Ari S., Vexler A., Barnea I., Starr A., Karaush V., Haif S., Ben-Yosef R. Curcumin: a potential radio-enhancer in head and neck cancer. Laryngoscope 2009, 119:2019-2026.
68. Lin J.K., Lin-Shiau S.Y. Mechanisms of cancer chemoprevention by curcumin. Proc. Natl. Sci. Counc. Repub. China B 2001, 25:59-66.
69. Kang G., Kong P.J., Yuh Y.J., Lim S.Y., Yim S.V., Chun W., Kim S.S. Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappab bindings in BV2 microglial cells. J. Pharmacol. Sci. 2004, 94:325-328.
70. Han S.S., Keum Y.S., Seo H.J., Surh Y.J. Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J. Biochem. Mol. Biol. 2002, 35:337-342.
71. Liu J.Y., Lin S.J., Lin J.K. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 1993, 14:857-861.
72. Plummer S.M., Holloway K.A., Manson M.M., Munks R.J., Kaptein A., Farrow S., Howells L. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999, 18:6013-6020.
73. Plummer S.M., Hill K.A., Festing M.F., Steward W.P., Gescher A.J., Sharma R.A. Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents. Cancer Epidemiol. Biomarkers Prev. 2001, 10:1295-1299.
74. Lin L.I., Ke Y.F., Ko Y.C., Lin J.K. Curcumin inhibits SK-Hep-1 hepatocellular carcinoma cell invasion in vitro and suppresses matrix metalloproteinase-9 secretion. Oncology 1998, 55:349-353.
75. Mohan R., Sivak J., Ashton P., Russo L.A., Pham B.Q., Kasahara N., Raizman M.B., Fini M.E. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J. Biol. Chem. 2000, 275:10405-10412.
76. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Lin B.R., Ming-Shiang W., Yu H.S., Jee S.H., Chen G.S., Chen T.M., Chen C.A., Lai M.K., Pu Y.S., Pan M.H., Wang Y.J., Tsai C.C., Hsieh C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer. Res. 2001, 21:2895-2900.
77. Rao C.V., Rivenson A., Simi B., Reddy B.S. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 1995, 55:259-266.
78. Kawamori T., Lubet R., Steele V.E., Kelloff G.J., Kaskey R.B., Rao C.V., Reddy B.S. Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res. 1999, 59:597-601.
79. Venkatraman M., Anto R.J., Nair A., Varghese M., Karunagaran D. Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. Mol. Carcinog. 2005, 44:51-59.
80. Bava S.V., Puliappadamba V.T., Deepti A., Nair A., Karunagaran D., Anto R.J. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J. Biol. Chem. 2005, 280:6301-6308.
81. Prusty B.K., Das B.C. Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int. J. Cancer 2005, 113:951-960.
82. Divya C.S., Pillai M.R. Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol. Carcinog. 2006, 45:320-332.
83. Singh M., Singh N. Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol. Cell. Biochem. 2009, 325:107-119.
84. Singh M., Singh N. Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in cervical cancer cells. Mol. Cell. Biochem. 2011, 347:1-11.
85. Madden K., Flowers L., Salani R., Horowitz I., Logan S., Kowalski K., Xie J., Mohammed S.I. Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer. Prostaglandins Leukot. Essent. Fatty Acids 2009, 80:9-18.
86. Maher D.M., Bell M.C., O'Donnell E.A., Gupta B.K., Jaggi M., Chauhan S.C. Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7. Mol. Carcinog. 2011, 50:47-57.
87. Javvadi P., Segan A.T., Tuttle S.W., Koumenis C. The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol. Pharmacol. 2008, 73:1491-1501.
88. Javvadi P., Hertan L., Kosoff R., Datta T., Kolev J., Mick R., Tuttle S.W., Koumenis C. Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Cancer Res. 2010, 70:1941-1950.
89. Sreekanth C.N., Bava S.V., Sreekumar E., Anto R.J. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene 2011, 30:3139-3152.
90. Bava S.V., Sreekanth C.N., Thulasidasan A.K., Anto N.P., Cheriyan V.T., Puliyappadamba V.T., Menon S.G., Ravichandran S.D., Anto R.J. Akt is upstream and MAPKs are downstream of NF-kappaB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. Int. J. Biochem. Cell Biol. 2011, 43:331-341.
91. Sultana R., Ravagna A., Mohmmad-Abdul H., Calabrese V., Butterfield D.A. Ferulic acid ethyl ester protects neurons against amyloid beta-peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J. Neurochem. 2005, 92:749-758.
92. Mohmmad Abdul H., Butterfield D.A. Protection against amyloid beta-peptide (1-42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer's disease. Biochim. Biophys. Acta 2005, 1741:140-148.
93. Joshi G., Perluigi M., Sultana R., Agrippino R., Calabrese V., Butterfield D.A. In vivo protection of synaptosomes by ferulic acid ethyl ester (FAEE) from oxidative stress mediated by 2,2-azobis(2-amidino-propane) dihydrochloride (AAPH) or Fe(2+)/H(2)O(2): insight into mechanisms of neuroprotection and relevance to oxidative stress-related neurodegenerative disorders. Neurochem. Int. 2006, 48:318-327.
94. Perluigi M., Joshi G., Sultana R., Calabrese V., De Marco C., Coccia R., Cini C., Butterfield D.A. In vivo protective effects of ferulic acid ethyl ester against amyloid-beta peptide 1-42-induced oxidative stress. J. Neurosci. Res. 2006, 84:418-426.
95. Di Domenico F., Perluigi M., Foppoli C., Blarzino C., Coccia R., De Marco F., Butterfield D.A., Cini C. Protective effect of ferulic acid ethyl ester against oxidative stress mediated by UVB irradiation in human epidermal melanocytes. Free. Radic. Res. 2009, 43:365-375.
96. Jayaprakasam B., Vanisree M., Zhang Y., Dewitt D.L., Nair M.G. Impact of alkyl esters of caffeic and ferulic acids on tumor cell proliferation, cyclooxygenase enzyme, and lipid peroxidation. J. Agric. Food Chem. 2006, 54:5375-5381.
97. Zheng L.F., Dai F., Zhou B., Yang L., Liu Z.L. Prooxidant activity of hydroxycinnamic acids on DNA damage in the presence of Cu (II) ions: mechanism and structure-activity relationship. Food Chem. Toxicol. 2008, 46:149-156.
98. Karthikeyan S., Kanimozhi G., Prasad N.R., Mahalakshmi R. Radiosensitizing effect of ferulic acid on human cervical carcinoma cells in vitro. Toxicol. In Vitro 2011.
99. Yu G.P., Hsieh C.C., Wang L.Y., Yu S.Z., Li X.L., Jin T.H. Green-tea consumption and risk of stomach cancer: a population-based case-control study in Shanghai, China. Cancer Causes Control 1995, 6:532-538.
100. Ji B.T., Chow W.H., Hsing A.W., McLaughlin J.K., Dai Q., Gao Y.T., Blot W.J., Fraumeni J.F. Green tea consumption and the risk of pancreatic and colorectal cancers. Int. J. Cancer 1997, 70:255-258.
101. Graham H.N. Green tea composition, consumption, and polyphenol chemistry. Prev. Med. 1992, 21:334-350.
102. Horie N., Hirabayashi N., Takahashi Y., Miyauchi Y., Taguchi H., Takeishi K. Synergistic effect of green tea catechins on cell growth and apoptosis induction in gastric carcinoma cells. Biol. Pharm. Bull. 2005, 28:574-579.
103. Nihal M., Ahmad N., Mukhtar H., Wood G.S. Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int. J. Cancer 2005, 114:513-521.
104. Baliga M.S., Meleth S., Katiyar S.K. Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clin. Cancer Res. 2005, 11:1918-1927.
105. Kondo T., Ohta T., Igura K., Hara Y., Kaji K. Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding. Cancer Lett. 2002, 180:139-144.
106. Fassina G., Vene R., Morini M., Minghelli S., Benelli R., Noonan D.M., Albini A. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin. Cancer Res. 2004, 10:4865-4873.
107. Qanungo S., Das M., Haldar S., Basu A. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis 2005, 26:958-967.
108. Ahmad N., Cheng P., Mukhtar H. Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochem. Biophys. Res. Commun. 2000, 275:328-334.
109. Liang Y.C., Lin-Shiau S.Y., Chen C.F., Lin J.K. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate. J. Cell. Biochem. 1999, 75:1-12.
110. Ahmad N., Feyes D.K., Nieminen A.L., Agarwal R., Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J. Natl. Cancer Inst. 1997, 89:1881-1886.
111. Chen Z.P., Schell J.B., Ho C.T., Chen K.Y. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett. 1998, 129:173-179.
112. Nanjo F., Honda M., Okushio K., Matsumoto N., Ishigaki F., Ishigami T., Hara Y. Effects of dietary tea catechins on alpha-tocopherol levels, lipid peroxidation, and erythrocyte deformability in rats fed on high palm oil and perilla oil diets. Biol. Pharm. Bull. 1993, 16:1156-1159.
113. Nakagawa T., Yokozawa T. Direct scavenging of nitric oxide and superoxide by green tea. Food Chem. Toxicol. 2002, 40:1745-1750.
114. Haenen G.R., Paquay J.B., Korthouwer R.E., Bast A. Peroxynitrite scavenging by flavonoids. Biochem. Biophys. Res. Commun. 1997, 236:591-593.
115. Scott B.C., Butler J., Halliwell B., Aruoma O.I. Evaluation of the antioxidant actions of ferulic acid and catechins. Free. Radic. Res. Commun. 1993, 19:241-253.
116. Sah J.F., Balasubramanian S., Eckert R.L., Rorke E.A. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J. Biol. Chem. 2004, 279:12755-12762.
117. Khan N., Afaq F., Saleem M., Ahmad N., Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res. 2006, 66:2500-2505.
118. Na H.K., Surh Y.J. Intracellular signaling network as a prime chemopreventive target of (-)-epigallocatechin gallate. Mol. Nutr. Food Res. 2006, 50:152-159.
119. Ahn W.S., Huh S.W., Bae S.M., Lee I.P., Lee J.M., Namkoong S.E., Kim C.K., Sin J.I. A major constituent of green tea, EGCG, inhibits the growth of a human cervical cancer cell line, CaSki cells, through apoptosis, G(1) arrest, and regulation of gene expression. DNA Cell Biol. 2003, 22:217-224.
120. Asif Siddiqui F., Naim M., Islam N. Apoptotic effect of green tea polyphenol (EGCG) on cervical carcinoma cells. Diagn. Cytopathol. 2011, 39:482-488.
121. Kuhn D.J., Burns A.C., Kazi A., Dou Q.P. Direct inhibition of the ubiquitin-proteasome pathway by ester bond-containing green tea polyphenols is associated with increased expression of sterol regulatory element-binding protein 2 and LDL receptor. Biochim. Biophys. Acta 2004, 1682:1-10.
122. Noguchi M., Yokoyama M., Watanabe S., Uchiyama M., Nakao Y., Hara K., Iwasaka T. Inhibitory effect of the tea polyphenol, (-)-epigallocatechin gallate, on growth of cervical adenocarcinoma cell lines. Cancer Lett. 2006, 234:135-142.
123. Yokoyama M., Noguchi M., Nakao Y., Pater A., Iwasaka T. The tea polyphenol, (-)-epigallocatechin gallate effects on growth, apoptosis, and telomerase activity in cervical cell lines. Gynecol. Oncol. 2004, 92:197-204.
124. Zhang Q., Tang X., Lu Q., Zhang Z., Rao J., Le A.D. Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol. Cancer Ther. 2006, 5:1227-1238.
125. Tudoran O., Soritau O., Balacescu O., Balacescu L., Braicu C., Rus M., Gherman C., Virag P., Irimie F., Berindan-Neagoe I. Early transcriptional pattern of angiogenesis induced by EGCG treatment in cervical tumor cells. J. Cell. Mol. Med. 2011.
126. Li M., He Z., Ermakova S., Zheng D., Tang F., Cho Y.Y., Zhu F., Ma W.Y., Sham Y., Rogozin E.A., Bode A.M., Cao Y., Dong Z. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol. Biomarkers Prev. 2007, 16:598-605.
127. Jacob J., Cabarcas S., Veras I., Zaveri N., Schramm L. The green tea component EGCG inhibits RNA polymerase III transcription. Biochem. Biophys. Res. Commun. 2007, 360:778-783.
128. Qiao Y., Cao J., Xie L., Shi X. Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells. Arch. Pharm. Res. 2009, 32:1309-1315.
129. Zou C., Liu H., Feugang J.M., Hao Z., Chow H.H., Garcia F. Green tea compound in chemoprevention of cervical cancer. Int. J. Gynecol. Cancer 2010, 20:617-624.
130. Bonfili L., Cuccioloni M., Mozzicafreddo M., Cecarini V., Angeletti M., Eleuteri A.M. Identification of an EGCG oxidation derivative with proteasome modulatory activity. Biochimie 2011, 93:931-940.
131. Kramer M.P., Wesierska-Gadek J. Monitoring of long-term effects of resveratrol on cell cycle progression of human HeLa cells after administration of a single dose. Ann. N. Y. Acad. Sci. 2009, 1171:257-263.
132. Sun A.Y., Simonyi A., Sun G.Y. The "French Paradox" and beyond: neuroprotective effects of polyphenols. Free Radic. Biol. Med. 2002, 32:314-318.
133. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
134. Alkhalaf M., El-Mowafy A., Renno W., Rachid O., Ali A., Al-Attyiah R. Resveratrol-induced apoptosis in human breast cancer cells is mediated primarily through the caspase-3-dependent pathway. Arch. Med. Res. 2008, 39:162-168.
135. Alkhalaf M. Resveratrol-induced apoptosis is associated with activation of p53 and inhibition of protein translation in T47D human breast cancer cells. Pharmacology 2007, 80:134-143.
136. Pozo-Guisado E., Merino J.M., Mulero-Navarro S., Lorenzo-Benayas M.J., Centeno F., Alvarez-Barrientos A., Fernandez-Salguero P.M. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int. J. Cancer 2005, 115:74-84.
137. Tang H.Y., Shih A., Cao H.J., Davis F.B., Davis P.J., Lin H.Y. Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther. 2006, 5:2034-2042.
138. Hu Y., Sun C.Y., Huang J., Hong L., Zhang L., Chu Z.B. Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin. Med. J. (Engl) 2007, 120:1672-1677.
139. Ahmad N., Adhami V.M., Afaq F., Feyes D.K., Mukhtar H. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin. Cancer Res. 2001, 7:1466-1473.
140. Heredia A., Davis C., Redfield R. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. J. Acquir. Immune Defic. Syndr. 2000, 25:246-255.
141. Docherty J.J., Fu M.M., Stiffler B.S., Limperos R.J., Pokabla C.M., DeLucia A.L. Resveratrol inhibition of herpes simplex virus replication. Antiviral Res. 1999, 43:145-155.
142. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer. Res. 2004, 24:2783-2840.
143. Harikumar K.B., Aggarwal B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7:1020-1035.
144. Sexton E., Van Themsche C., LeBlanc K., Parent S., Lemoine P., Asselin E. Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol. Cancer 2006, 5:45.
145. Lin H.Y., Sun M., Tang H.Y., Simone T.M., Wu Y.H., Grandis J.R., Cao H.J., Davis P.J., Davis F.B. Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. J. Cell. Biochem. 2008, 104:2131-2142.
146. Lin C., Crawford D.R., Lin S., Hwang J., Sebuyira A., Meng R., Westfall J.E., Tang H.Y., Yu P.Y., Davis P.J., Lin H.Y. Inducible COX-2-dependent apoptosis in human ovarian cancer cells. Carcinogenesis 2011, 32:19-26.
147. Lin H.Y., Tang H.Y., Davis F.B., Davis P.J. Resveratrol and apoptosis. Ann. N. Y. Acad. Sci. 2011, 1215:79-88.
148. Lee P.P., Hwang J.J., Murphy G., Ip M.M. Functional significance of MMP-9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells. Endocrinology 2000, 141:3764-3773.
149. Waas E.T., Lomme R.M., DeGroot J., Wobbes T., Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br. J. Cancer 2002, 86:1876-1883.
150. Woo J.H., Lim J.H., Kim Y.H., Suh S.I., Min D.S., Chang J.S., Lee Y.H., Park J.W., Kwon T.K. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene 2004, 23:1845-1853.
151. Toussaint-Smith E., Donner D.B., Roman A. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 2004, 23:2988-2995.
152. Lopez-Ocejo O., Viloria-Petit A., Bequet-Romero M., Mukhopadhyay D., Rak J., Kerbel R.S. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 2000, 19:4611-4620.
153. Kim S.H., Juhnn Y.S., Kang S., Park S.W., Sung M.W., Bang Y.J., Song Y.S. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1,2 and PI3K/Akt. Cell. Mol. Life Sci. 2006, 63:930-938.
154. Tang X., Zhang Q., Nishitani J., Brown J., Shi S., Le A.D. Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells. Clin. Cancer Res. 2007, 13:2568-2576.
155. Hsu K.F., Wu C.L., Huang S.C., Wu C.M., Hsiao J.R., Yo Y.T., Chen Y.H., Shiau A.L., Chou C.Y. Cathepsin L mediates resveratrol-induced autophagy and apoptotic cell death in cervical cancer cells. Autophagy 2009, 5:451-460.
156. Rezk Y.A., Balulad S.S., Keller R.S., Bennett J.A. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am. J. Obstet. Gynecol. 2006, 194:e23-e26.
157. Gupta S.C., Kannappan R., Reuter S., Kim J.H., Aggarwal B.B. Chemosensitization of tumors by resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215:150-160.
158. Talwar G.P. A clinical study on the clearance of human papilloma virus (HPV) infection in uterine cervix by Basant (a polyherbal cream) and curcumin soft gelatin capsule in females infected with HPV Clinical Trial Registry - India 2008, National Institute of Medical Statistics (ICMR, India, CTRI/2008/091/000095).
159. Ahn W.S., Yoo J., Huh S.W., Kim C.K., Lee J.M., Namkoong S.E., Bae S.M., Lee I.P. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur. J. Cancer Prev. 2003, 12:383-390.
160. Vang O., Ahmad N., Baile C.A., Baur J.A., Brown K., Csiszar A., Das D.K., Delmas D., Gottfried C., Lin H.Y., Ma Q.Y., Mukhopadhyay P., Nalini N., Pezzuto J.M., Richard T., Shukla Y., Surh Y.J., Szekeres T., Szkudelski T., Walle T., Wu J.M. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 2011, 6:e19881.
161. Patel K.R., Scott E., Brown V.A., Gescher A.J., Steward W.P., Brown K. Clinical trials of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215:161-169.
162. Patel K.R., Brown V.A., Jones D.J., Britton R.G., Hemingway D., Miller A.S., West K.P., Booth T.D., Perloff M., Crowell J.A., Brenner D.E., Steward W.P., Gescher A.J., Brown K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010, 70:7392-7399.
163. Brown V.A., Patel K.R., Viskaduraki M., Crowell J.A., Perloff M., Booth T.D., Vasilinin G., Sen A., Schinas A.M., Piccirilli G., Brown K., Steward W.P., Gescher A.J., Brenner D.E. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010, 70:9003-9011.